Great result :-) very good things to come imo....US PATENT...

Great result :-) very good things to come imo....

US PATENT ALLOWANCE CONFIRMS PHYLOGICA’S DOMINANCE IN NEW
CLASS OF DRUGS
Perth, Wednesday 6th June 2007
Key Points:
• New US patent allowed (claiming priority until 2023)
• Confirms novelty of Phylomer® concept as a source of new drug candidates
• Confirms clear ownership over all current and future Phylomer® libraries
Australian drug discovery company Phylogica Limited (ASX: PYC) today announced
that another key US Patent has been allowed that will protect its Phylomer® libraries
and construction methods that are the source of its exclusive peptide drug candidates.
Phylogica’s Vice President of Drug Discovery and scientific founder, Dr Paul Watt, said
the allowed claims in the US patent application gives Phylogica clear ownership over
all current and future gene-based Phylomer® libraries and confirms the company’s
dominance in this exciting new class of drugs.
“Phylogica’s Phylomer® libraries were first patented in 2000 and have since yielded
multiple drug candidates that have been proven effective in pre-clinical models of a
range of inflammatory diseases including head trauma, stroke, and severe burns,” Dr
Watt said.
Phylomers® are stable fragments of naturally-occurring proteins with the ability to bind
tightly to target proteins and inactivate them as a result. Phylomers can be selected
from libraries for their activity against specific disease target proteins
The company is progressing to commercialisation with its anti-inflammatory drug
candidates developed in partnership with Ireland-based Opsona Therapeutics.
Phylogica’s CEO, Dr Stewart Washer, said the allowance of the patent provides greater
protection and acknowledges the novelty of the Phylomer® concept.
“The allowance of the patent confirms our dominance in this cutting edge class of
drugs that clearly extends beyond antibodies in a number of major areas, “ Dr Washer
said.
“We’ve shown that Phylogica’s Phylomer® peptides can work both inside and outside
the cell, also having the advantage of being much smaller molecules that can be more
specifically targeted and delivered, as well as being potentially much cheaper to
produce.”
Phylogica now has 10 patent families and 8 allowed patents, including several patents
granted in the major markets of the US and Europe.